The plasma levels of prostanoids and plasminogen activator inhibitor-1 in primary and secondary thrombocytosis

Clinical and Applied Thrombosis/Hemostasis

Volumn 11, Issue 2, 2005, Pages 197-201

  Birdane, A ^a   Haznedaroglu I C ^a   Bavbek, N ^b,c   Kosar A ^b   Buyukasik Y ^a   Ozcebe O ^a   Dundar S V ^a   Kirazli, S ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b FATIH UNIVERSITY MEDICAL SCHOOL   (Turkey)

^c NONE   (Turkey)

Author keywords

6 Keto PGF1 ; Plasminogen activator inhibitor type 1; Thrombocytosis; Thromboxane A2

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ARACHIDONIC ACID; ENDOPEROXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTANOID; THROMBOXANE A2;

ADULT; ARACHIDONIC ACID METABOLISM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HUMAN; MALE; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS;

ADOLESCENT; ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDINS; THROMBOCYTOSIS;

EID: 17444420092     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960501100209     Document Type: Article

References (44)

1. Schaffer AI. Bleeding and thrombosis in myeloproliferative disorders. Blood 1984;64:1.
2. Schaffer AI. Essential thrombocytemia. Progr Haemost Thromb 1991;10:69.
3. Fenaux P, Simoni M, Caulier MT, et al. Clinical course of essential thrombocytemia in 147 cases. Cancer 1990;66:549.
4. Lindahl TL, Ohlsson PI, Wiman B. The mechanism of the interaction between human plasminogen activator. Biochem 1990;265:109.
5. Van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor and its function in fibrinolysis: an update. Fibrinolysis 1995;9:263.
6. Alessi MC, Chomiki N, Berthier R, et al. Detection of plasminogen activator inhibitor-1 mRNA in human megakaryocytes by in situ hybridization. Thromb Haemost 1994;72:931.
7. Kokle BA, Schick PK, He X, et al. Plasminogen activator inhibitor 1 mRNA is expressed in platelets and megacaryocytes and the megakayoblastic cell line CHRF-288. Arterioscler Thromb 1993;13:669.
8. Sprengers ED, Akkerman JW, Jansen BG. Blood platelet plasminogen activator inhibitor in human blood. Thromb Haemost 1986;55:325.
9. Booth NA, Simpson AJ, Croll A, et al. Plasminogen activator inhibitor in plasma and platelets. Br J Haematol 1988;70:327.
10. Hadjez JM, Combe S, Horellou MH, et al. Heterogenous mechanisms responsible for reduced fibrinolytic capacity in patients with a history of venous thrombosis. Fibrinolysis 1994;8:543.
11. Patrassi GM, Sartori MT, Saggiorato G, et al. Familial thrombophilia associated with high levels of plasminogen activator inhibitor. Fibrinolysis 1992;6:99.
12. Patrassi GM, Sartori MT, Viero ML, et al. The fibrinolytic potential in patients with Cushing's disease: A clue to their hypercoagulable state. Blood Coag Fibrinol 1992;3:789.
13. Patrassi GM, Sartori MT, Rigotti P, et al. Reduced fibrinolytic potential one year after kidney transplantation. Transplantation 1995;59:1416.
14. Russell NH, Salmon J, Keenan JP, Bellingham AJ. Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative disorders. Thromb Res 1981;22:389.
15. Jubelirer SJ, Russell F, Vaillancourt R, Deykin D. Platelet arachidonic acid metabolism and platelet function in ten patients with chronic myelogenous leukemia. Blood 1980;56:728.
16. Keenan JP, Wharton J, Shepherd AJN, Bellingham AJ. Defective platelet lipid peroxidation in myeloproliferative disorders: A possible defect of prostaglandin synthesis. Br J Haematol 1977;35:275.
17. Okuma M, Ukino H. Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders. Blood 1979;54:1258.
18. Defreyn G, Deckmyn H, Vermylen J. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2. Thromb Res 1982;26:389.
19. Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980;17:317.
20. Langley R. Practical Statistics. New York, Dover, 1971.
21. Mehta J, Metha P, Lawson DL, et al. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: Evidence for synthesis of prostacyclin by leukocaytes from platelet derived endoperoxides. J Lab Clin Med 1985;106:246.
22. Declerck PJ, Alessi MC, Verstreken M, et al. Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibody-based enzyme-linked immunoassay. Blood 1988;71:220.
23. Erikson E, Ranby M, Gyrender E, Risberg B. Determination of plasminogen activator inhibitor in plasma using t-PA and chromogenic single point poly-D-lysine stimulated assay. Thromb Res 1988;50:91.
24. Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocytemia. A retrospective study of 103 patients. Cancer 1991;67:2926.
25. Pearson TC, Wethereley-Mein G. Vascular occlusive episodes and venous hematocrit in primary proliferative polycythemia. Lancet 1978:1219.
26. Randi ML, Fabris F, Tison T, et al. Prevalance of specific thrombotic accidents in patients with thrombocytosis. Haematologica 1993;25:149.
27. Fabris F, Randi ML, Sbrojavacca R, et al. The possible value of platelet aggregation studied in patients with increased platelet number. Blut 1981;43:279.
28. Pareti FJ, Gugliotta L, Mannucci L, et al. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders. Thromb Haemost 1982;47:84.
29. Wehmeier A, Scharp RE, Flicke S, Schneider W. Bleeding and thrombosis in chronic myeloproliferative disorders: Relation of platelet disorders to clinical aspects of the disease. Haemostasis 1989;19:251.
30. Luzzatto G, Fabris F, Mazzuccato M, Girolami A. PF4 versus βTG as evidence for platelet activation in myeloproliferative disorders. Scand J Haematol 1985;35:299.
31. Bellucci S, Ignatova E, Jaillet N, Boffa MC. Platelet hyperactivation in patients with essential thrombocytemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, Protein S, PAI-1, t-PA and vWF. Thromb Haemost 1993;70:736.
32. Preston FE, Martin JF, Stewart RW, Davies-Jones GAB. Thrombocytosis, circulating platelet aggregates and neurological dysfunction. Br Med J 1979;2:1561.
33. Patrassi GM, Sartori MT, Rigotti P, et al. Coagulation and fibrinolysis during the first year of immunosuppressive treatment in renal transplantation: Correspondence between hypercoagulable state and steroid therapy. Clin Appl Thromb/Haemost 1995;1:277.
34. Patrassi GM, Sartori MT, Ruffatti A, et al. Fibrinolytic pattern in recurrent spontaneous abortions: No relationship between hypofibrinolysis and anti-phospholipid antibodies. Am J Hematol 1994;47:266.
35. Bazzan M, Tamponi G, Gallo E, et al. Fibrinolytic imbalance in essential thrombocytemia: Role of platelets. Haemostasis 1993;23:38.
36. Pannocchia A, Garis G, Giorgianni A, et al. Molecular characteristics of human plasma, platelet and vascular cell PAI-1. Comparison between normal and thrombocytemic subjects. Fibrinolysis 1994;8:28.
37. Canceras JA, Garcia-Avello A, Garcia-Frade LJ. Elevated plasma levels of plasminogen activator inhibitor in essential thrombocythemia and polycthemia vera. Haemostasis 1994;24:311.
38. Harlan JM, Harker LA. Hemostasis thromboembolic disorders. The role of arachidonic acid metabolites in platelet-vessel wall interactions. Med Clin North Am 1981;65:855.
39. Zahavi C, Zahavi M, Firsteter E, et al. An abnormal pattern of multiple platelet function abnormalities and increased thromboxane generation in patients with primary thrombocytosis and thrombotic complications. Eur J Haematol 1991;47:326.
40. Zahavi J, Zahavi M, Firsteter B, et al. An abnormal pattern of multiple platelet function abnormalities and increased thromboxane generation in patients with primary thrombocytosis and thrombotic complications. Eur J Haematol 1991;47:326.
41. Landolfi R, Ciabattoni P, Patrignani P, et al. Increased thromboxane biosynthesis in patients with polycythemia vera: Evidence for aspirin-suppressible platelet activation in vivo. Blood 1992;80:1965.
42. Rocca B, Ciabattoni G, Tartaglione R, et al. Increased thromboxane biosynthesis in essential thrombocytemia. Thromb Haemostas 1995;74:1225.
43. Schafer IA. Deficiency of platelet lipooxygenase activity in myeloproliferative disorders. N Engl J Med 1982;306:381.
44. Cortelazzo S, Viero P, Morelli C, et al. Normal vascular prostacyclin generation in patients with chronic myeloproliferative disorders. Thromb Res 1985;39:139.